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Abstract: 
Background: The increased use of antidepressant drugs (ADs) improved the response to the needs of care although some 
community surveys have shown that subjects without lifetime psychiatric diagnosis (anxiety/depression) used ADs. 
Objectives: To evaluate the appropriateness and amount of prescription of psychotropic drugs in people with lifetime  
diagnosis of Major Depressive Disorder (MDD) by means of community survey with a semi-structured interview as a di-
agnostic instrument, administered by clinicians. 
Methods: Study design: community survey. 
Study population: samples randomly drawn, after stratification from the adult population of municipal records. Sample size: 
4.999 people were drawn in 7 centres of 6 Italian regions. 
Tools: questionnaire on psychotropic drug consumption, prescription, health services utilization; Structured Clinical In-
terview for DSM-IV modified (ANTAS); Training: interviewers were trained psychologists or medical doctors. 
Results: 3.398 subjects were interviewed (68% of the recruited sample). The lifetime prevalence of DSM-IV MDD was 
4.3% in males and 11.5% in females; antidepressant drugs were taken by 4.7% of subjects, 2.9% male and 5.9% female. 
38% of males and 57% of females with lifetime diagnosis of MDD were taking ADs.  
Conclusions: Compared with studies using lay interviewers and structured tools the prevalence of the MDD was quite 
lower; ADs use was higher and tallied well with the data regarding antidepressant sales in Italy; the correspondence be-
tween lifetime diagnosis of MDD and ADs use was closer. 
Keywords: Antidepressant drugs, major depressive disorders, bipolar disorders, community survey, lifetime prevalence. 
INTRODUCTION 
Direct expenditure for ADs in Italy incremented at a 25% 
rate from 2000 to 2002 [1]. A number of population surveys 
have shown that the ADs usage increase is associated with 
an improved response to patients’ needs of those diagnosed 
with depression. However, the appropriateness of ADs pre-
scription is still open to debate. For more than a decade 
(1991 to 2002), in a community repeated survey performed 
in the Italian region of Sardinia, the number of individuals 
with a defined diagnosis of depression while taking ADs, 
increased from 8% to 40% [2]. The proportion of adults in 
the community who took antidepressants was 4.2% in 2002. 
However, 60% of subjects diagnosed with Depressive Epi-
sode (X International Classification of Diseases [ICD-10], 
[3]) did not have proper pharmacological treatment. On the 
other hand, a relevant proportion of subjects without lifetime  
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psychiatric diagnosis (anxiety and/or depression) used anti-
depressants. Pharmacologic therapy was managed by psy-
chiatrists in 44.2% of cases, but ADs were prescribed by 
general practitioners (GPs) in 31.8% of cases [2]. 
It has been hypothesised that a relevant proportion of 
ADs prescriptions was addressed to treat subsyndromal dis-
orders. In primary care, physicians label anxiety and affec-
tive disorders as clinical conditions that do not meet Diag-
nostic Statistical Manual (DSM) IV [4] definitional thresh-
olds for axis I anxiety or mood disorders [5]. Subsyndromal 
depression and anxiety are clinically relevant and of impor-
tance in public health because of pervasive impairment of 
psychosocial functions, a high rate of medical co-morbidity 
and a high rate of service utilization. Controversially, there is a 
lack of agreement about the use of antidepressants in sub-
syndromal depression and evidence from clinical trials is 
scarce. A non-replicated study of Paykel [6] found that anti-
depressants were no more efficacious than placebo in pa-
tients with subsyndromal depression. More recently, Rocca 
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pram can improve depressive symptoms and cognitive func-
tions of minor depressive disorders and subsyndromal de-
pressive symptomatology in elderly and non demented pa-
tients in a 1 year non-randomized follow-up clinical trial. On 
the contrary, a large number of researches found the efficacy 
in counseling and psychosocial therapies [8]. 
STUDY OBJECTIVES 
The general study objective is to evaluate the appropri-
ateness and amount of over and under-psychotropic drug 
prescription in different Italian areas, with a special focus on 
the general use of antidepressants. 
As for a diagnostic instrument, we use a tool derivate 
from defined and validated international semi-structured 
interviews that are administered by expert clinicians.  
In this first report we present the data among the lifetime 
prevalence of major depressive disorders. This also includes 
the prevalence of anti-depressant drug use in the sites of the 
research and the appropriateness of the AD prescriptions 
against the clinical diagnosis. 
METHODS  
Design 
The proposed study design is a community survey.  
Face to face interviews were carried out at candidates’ 
homes. 
Recruitment Methods and Study Sample  
Study sample was randomly drawn from the adult popu-
lation of municipal records in seven different areas including 
different Italian locations with wide variations in socioeco-
nomic conditions and prescriptive patterns. This included: 
Sicily (Catania), Sardinia (Sulcis), Puglia (Bari) in the South, 
Tuscany (Florence and Pisa) and Abruzzo (L’Aquila) in cen-
tral Italy and Friuli-Venezia Giulia (Udine) in northern Italy. 
In each area, both an urban and a rural subarea were selected. 
The urban subareas were Iglesias in Sulcis (Sardinia), Ca-
tania in Sicily, Bari in Puglia, Pisa in Tuscany and Udine in 
Friuli-Venezia Giulia. A third of the sample in each centre 
was drawn from 3 variously populated municipalities; less 
than 2.000, from to 2.001 to 10.000 in-habitants and from 
10.001 to 20.000 inhabitants. They were also randomly 
drawn from the municipalities of the same province not bor-
dering the urban area. 
The sample of Udine was only urban and Florence was 
only rural. 
Randomisation was performed after stratification by sex 
and four different age groups (18-24; 25-44; 45-64; >64). 
Using the above mentioned methodology, a sample of 
4.999 people was drawn from the 7 centres. The size of the 
sub drawn samples were: 704 in L’Aquila; 971 in Bari; 666 
in Catania; 846 in Florence; 465 in Sulcis; 464 in Pisa and 
882 in Udine. 
Included in each person’s sample was their general prac-
titioner’s name which was obtained from the general practi-
tioner’s health authority registry (practically each Italian 
resident is registered with a GP). The relevant general practi-
tioners were asked to sign an invitation to their patients for 
survey collaboration. 
Subjects were contacted and interviewed at home by the 
local coordinator of the study. 
Interview, Tools and Study Assessment  
Interviews consist of the following tools: 
1. Ad hoc form to assess basic demographic data 
2. a questionnaire on psychotropic drug consumption, pre-
scription circumstances and health services utilization [3]; 
3. the “Advanced Neuropsychiatric Tools and Assessment 
Schedule” (ANTAS) a semi-Structured Clinical Inter-view 
derived in part from the non patient version (SCIDI/NP) for 
DSM-IV [9] to assess the presence of full or sub-threshold 
psychiatric disorders (this, as already said, requires a clinical 
competence to be administered as planned in the study pro-
tocol). A reliability study of the diagnosis derived for the 
ANTAS against SCID was preliminarily carried out and the 
results were previously published [10]. The reliability con-
cerning mood and anxiety diagnosis with SCID was meas-
ured with a mean K of 0.85 [10]. 
Interviewers asked the interviewees to show them their 
drug boxes and were provided with a folder to retain all of 
the psychotropic drug box covers. 
For all the subjects’ were ascertained antidepressant 
drugs consumption (tricyclics, SSRI, SNRI and NARI), as 
positive at use were identified subjects assuming antidepres-
sants drugs at therapeutic dosages for every day at least the 
15 days before the interview. 
Interviewers and Training 
Interviewers were selected from psychologists and medi-
cal doctors with at least two years experience of clinical psy-
chiatric work after graduation. 
They received common intensive training in the use of 
the research instrument and administration of home inter-
views. 
Intensive training was carried out by the Coordination 
Unit. 
Interviewers were provided with a laptop computer and 
hoc software to immediately record data. 
Two assistant researchers from the Coordinating Unit 
travelled to each field unit, interviewed at least 7 patients and 
three normal control subjects that were then re-interviewed 
by the local interviewers. Differences in results were dis-
cussed and sorted out. The diagnosis reliability between co-
ordinator centre researchers and each other unit had an aver-
age higher than K>80. 
Monitoring and Quality Control 
Interview quality was monitored by cross examining the 
interviewers every three months and having at least 120 in-
terviews that were repeated by different interviewers. This 
task was then carried out by the “Associazione Università 
Europea del Mediterraneo” in collaboration with the coordi-
nator centre. 96    Clinical Practice & Epidemiology in Mental Health, 2010, Volume 6  Carta et al. 
Data checks and editing were periodically accomplished 
and input software assured that the easiest checks were done 
automatically. 
Data Collection  
Data collection and the modalities for databank creation 
may be checked directly on the official research site 
(http://www.mooditaly.com/) with an appropriate password. 
The site was used to load peripheral centres data to the data-
bank and for monitoring. Data was not nominal at source and 
each subject is identifiable with a code number. 
Statistical Considerations 
Statistical analysis templates were developed well before 
the data collection conclusion. Basic univariate and multi-
variate analyses were planned with 95% confidence limits. 
Sample Size 
It was envisaged that from 60% to 65% of the original 
sample (4.800 planned sample, 800 interviews from 6 cen-
tres) members may take part in the survey (5% of members 
were expected to be deceased or moved, 10% were expected 
to be non retrievable and 20% were considered the refusal 
rate) for an expected total about 3.000 interviewed people. 
This sample size was expected to provide a 95% confidence 
interval of +0.036% of the expected prevalence summary 
estimate of 4% of both antidepressant consumption and bipo-
lar disorders as MDQ positives (relative standard error being 
around 7%). 
The final sample of 4.999 subjects from 7 centres will be 
explained in the results section and the proportion that took 
part in the study was 68% which was nearly the expected 60-
65%. 
Ethical Aspects 
A signed informed consent for each candidate. The study 
was approved by the ethical committee of the Italian Na-
tional Health Institute (Rome). 
RESULTS 
Table  1  summarizes the characteristics of the enrolled 
sample by centre, sex and rate of the non-interviewed (de-
ceased, uncontacted, transferred or refusal). Sub-sample size 
per centre varies from 464 in Pisa to 972 in Bari. The highest 
non-interviewed rate was in Pisa (66.8%) the lowest was in 
Bari (17.1). 
Table  2  summarizes the characteristics of the enrolled 
sample by age, sex and the rate of non-interviewed. The 
male percentage of the non-interviewed was higher than the 
female (41% versus 25%). The best adhesion rate was in the 
older age group for both for males and females. 
For measuring the comparison between interviewed and 
randomized sub samples, reports are in 2X2 tables, for each 
of the 8, by age/sex. Each table consists of 4 cells: 
Table 1. Enrolled Sample by Centre, Sex and Rate of the Non-interviewed (Deceased, Uncontacted, Transferred or Refusal) 
Centre 
Interviewed 
Males 
Interviewed 
Females 
Total Interviewed 
Non 
Interviewed 
Total Sample 
Randomized 
% of Non- 
Interviewed 
L’Aquila  253  300 553 151 704 21.4 
Bari 384  421 805 167 972 17.2 
Catania  210  294 504 162 666 24.3 
Florence  266  422 688 158 846 18.9 
Sulcis  (Sardinia)  108  198 306 159 465 34.1 
Pisa 60 94  154 310 464 66.8 
Udine  156  232 388 494 882 56.0 
Total 1437  1961  3398 1601 4999 32.0 
 
Table 2. Enrolled Sample Characteristics by Age, Sex and the Non-Interviewed Rate 
Age 
Interviewed 
Males 
% of Total 
Non- 
Interviewed 
% of Non- 
Interviewed 
Interviewed 
Females 
% of Total 
Non- 
Interviewed 
Females 
% of Non- 
Interviewed 
18-24  192 14 180 48 241 12  97  29 
25-44  499 35 378 44 614 31 226 27 
45-64  460 31 287 39 707 37 242 26 
>64  286 20 140 33 399 20  80  17 
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Cell a: interviewed per sex and age (e.g. male 18-24) Cell 
b: randomized by the same sex and age group, 
Cell c: interviewed for all the others grouped by sex (e.g. 
male > 24). 
Cell d: randomized sample for all other groups. 
We calculate the 2, with 1 DF measuring in the cell, with 
the probability that the interviewed sample may differ from 
the randomized sample. Results are summarized in Table 3. 
No significant statistical difference was found between 
the interviewed sub-samples and randomised sub-samples. 
The greatest difference was in the older age groups due to 
the better adhesion rate of both for male and female samples 
in these groups. 
Table 4 shows the MDD lifetime prevalence by centre 
and sex. The prevalence in females was confirmed higher 
than in men (11.5% versus 4.3% in the overall sample 
2=47.5 with 1DF P=0.0001 Odds Ratio 2.6), the overall rate in 
the sample was 8.5%. 
In the centres, the point prevalence varies in males from 
1.8 (Sulcis) to 10.0% (Pisa) and in females from 5.2 (Flor-
ence) to 21.2 (Sulcis). Differences were without statistical 
significance in men (Comparison with centres, 2 with 6DF 
and Bonferroni correction, 2=9.96, P=0.12) but reached sta-
tistical significance in females (Comparison with centres, 2 
with 6DF and Bonferroni correction, 2=48.3, P<0.0001). 
Table 5 indicates the lifetime prevalence of MDD per age 
and sex. 
Table  6  indicates the statistical differences in lifetime 
prevalence of MDD as per age and sex. Males had the high-
est prevalence in older age groups (7.3%) but the difference 
with age 18-24 (used as pilot) didn’t become of statistical 
significance. In women the age at risk was 45-64 with 13% 
of lifetime prevalence (OR versus 18-24 was 1.9, 2 1 df 
=4.8, P<0.05). 
Table 7 shows the use of antidepressants in the 7 com-
munities. The use is indicated as positive if the subjects took 
antidepressants: in the last 15 days, almost every day or at 
least one antidepressant among tricyclics, SSRI, SNRI or 
NARI at therapeutic dosages. The usage in the total sample 
was 4.7%, 2.9% in males and 5.9% in females (OR= 1.9, 2 
with 1df = 12.0 P< 0.0001). Comparison between centres 
reached statistical significance both in men and females, (2 
with 6DF and Bonferroni correction) men 2=35.6, P<0.0001; 
females 2=29.9, P<0.0001. In men the centre with lowest use 
was Catania (0%) and highest was Florence (7.5%), in fe-
Table 3. Comparison Between Interviewed and Randomized Sub Samples 
Age and Sex  Interviewed Randomized  2 (1DF)  P 
Male 18-24  192  372  2.5  0.10 
Male 25-44  498  876  0.6  0.42 
Male 45-64  441  728  0.1  0.99 
Male >64  286  426  3.2  0.09 
Female 18-24  241  338  0.39  0.53 
Female 24-44  609  835  0.45  0.51 
Female 45-64  703  945  0.005  0.81 
Female >65  399  479  2.3  0.12 
 
Table 4. Lifetime Prevalence of MDD by Centre and Sex 
Centre  Male Sample  % of MDD 
Female 
Sample 
% of MDD 
L’Aquila 253  3.9  300  11.0 
Bari 384  2.9  421  5.2 
Catania 210  5.2  294  10.2 
Florence 266  5.6  422  8.8 
Sulcis (Sar)  108  1.8  198  21.2 
Pisa 60  10.0  94  20.2 
Udine 156  5.1  232  14.2 
Total 1437  4.3  1961  11.5 
 
Comparison with centres (2 with 6DF and Bonferroni correction): Male 2
=9.96 P
=0.126; female 2
=48.2 P<0.001.  98    Clinical Practice & Epidemiology in Mental Health, 2010, Volume 6  Carta et al. 
male the highest was L’Aquila (9.0%) the lowest Bari 
(2.3%). 
Table 8 shows the community use of antidepressants in 
people with a lifelong diagnosis of MDD. We chose the life-
time prevalence because some people without symptoms 
who met the criteria for the diagnosis may have had an epi-
sode in the past and may have had the control of the symp-
toms by use of antidepressants. This may have been negative 
at the point of prevalence but may have been using antide-
pressants in a rationale way. As expected, due to the higher 
rate of depressive episodes, the use of antidepressants in de-
pressed subjects is higher in females than in men 57% in 
contrast to 38% (OR=2.8, 2 with 1df =14.0 P<0.0001). To 
be taken into account is if we consider the proportion of us-
ers among the depressed, there is not statistical diference 
(OR=2.1, 2 with 1df =3.5, P=0.60). 
Comparison among centres didn’t reach statistical sig-
nificance in men (2 with 6DF and Bonferroni correction 
2=1.9, P=0. 13) but in females the difference was of statisti-
cal significance (2 with 6DF and Bonferroni correction 
2=14.4, P=0.025). In men, the centre with highest use in the 
depressed was Bari (100%) and lowest was Florence (7.5%), 
in females the highest were Pisa and Bari (80%) the lowest 
was Udine (33%). 
More than 50% (63% in females and 73% in males) of 
people were assuming antidepressant drugs without a life-
time diagnosis of MDD. 
Table 5. Lifetime Prevalence of MDD by Age and Sex 
Age  Male Sample  N° of MDD  %  Female 
Sample 
N° of MDD  % 
18-24 192  6  3.1  241  16 6.6 
25-44 499  20  4.0  614  74  12.0 
45-64 460  16  3.5  707  92  13.0 
>64 286  21  7.3 399  44  11.2 
 
Table 6. Statistical Differences in Lifetime Prevalence of MDD by Age and Sex 
Age Male  % 
Odds 
Ratio 
Cl 95% 
2 
(1df) 
P 
Female 
% 
OR Cl  95% 
2 
(1df) 
P 
18-24  3.1  =  =  =  6.6 =    =  = 
25-44 4.0  1.2 
0.44 to 
3.2 
0.10  NS  12.0  1.7  0.9 to 3.0  3.4  NS 
45-64 3.5  1.1 
0.65 to 
1.8 
0.10  NS  13.0  1.9  1.6 to 3.5  4.8  P<0.05 
>64 7.3 2.5 
0.9 to 
6.8 
3.13  NS  11.2  1.7  0.87 to 3.3  2.4  NS 
Table 7. Use of Antidepressant Drugs by Centre 
Centre Male  Sample 
N° of Antidepressants 
Users  % 
Female 
Sample 
N° of Antidepressants 
Users  % 
L’Aquila 253  5  2.0 300  27  9.0 
Bari 384  3 0.8  421  10  2.3 
Catania 210  0  0  294  11  3.7 
Florence 266  20  7.5 422  41  7.3 
Sulcis (Sar)  108  4  3.7  198  8  4.0 
Pisa 60  3 5  94  5  5.3 
Udine 156  7  4.5  232  15  6.4 
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The use of antidepressants by age and sex is reported in 
Table 9. 
Table 10 shows the statistical differences in use of anti-
depressant drugs per age and sex. The use of antidepressants 
increased by age and females older than 45 years old had 
antidepressant use higher than those in the younger age 
groups. 
DISCUSSION 
The MDD prevalence identified in the community by 
means of a “clinical method”, using clinicians as interview-
ers and a semi-structured diagnostic tool, was quite lower 
than the prevalence identified in the same cultural setting in 
studies using lay interviewers and structured tools. In fact, 
the Esemed project found a 10% lifetime rate of MDD in 
Italy [11] in a representative nationwide sample. We must 
also point out tha the prevalence of MDD in Italy was the 
lowest of all six European countries participating in the pro-
ject. In this perspective, our study seems to confirm the low 
rate of mood disorders shown in most Italian community 
surveys [12]. 
Compared with the figures reported by the studies that 
used lay interviewers, the use of antidepressant drugs found 
in this study was decidedly higher. For example, the Esemed 
study reported use of antidepressant drugs in 1% of the com-
munity [11]. The results of this study demonstrate tallies 
well within the data regarding the sales of antidepressants in 
Italy: the Report on Mental Health in Europe shows that di-
rect expenditure for AD incremented around 25% in Italy 
from 2000-2002. A rate which is the highest among the top-
ranking European markets [1]. 
Data produced by the Italian Health Ministry shows that 
expenditure augmentation has paralleled that of the prescrip-
tions [13]. 
The rate of antidepressant use in this study is similar of 
those found by a Sardinian survey in 2003, in which the rate 
of adults in the general population who took antidepressants 
was 4.2% [3]. 
Table 8. Use of Antidepressant Drugs by Centre in Subjects with a Lifelong MDD Diagnosis 
Centre Male  Sample 
N° of Antidepres- 
sants Users 
% 
Of all Users 
Female 
Sample 
N° of 
Antidepressants Users 
% 
Of All Users 
L’Aquila 253  2  40 300  15  55 
Bari 384  3  100  421  8  80 
Catania 210  0  100  294  5  45 
Florence 266  7  35 422  20  64 
Sulcis (Sar)  108  2  50  198  4  50 
Pisa 60  0  100  94  4  80 
Udine 156  2  28  232  5  33 
Total  1437  16  38  1961 61 57 
 
Table 9. Use of Antidepressants by Age and Sex 
Age Male  Sample 
N° of Antidepres- 
sants Users  % 
Female 
Sample 
N° of antidepres- 
sants Users  % 
18-24 192  3  1.6  241  5  2.3 
25-44 499  13 2.6  614  26  4.2 
45-64 460  12 2.6  707  58  8.2 
>64 286  14  4.9  399  28  7.4 
 
Table 10. Statistical Differences in Use of Antidepressants Drugs by Age and Sex  
Age  Male %  Odds Ratio  Cl 95% 
2 
(1df) 
P 
Female 
% 
OR Cl  95% 
2 
(1df) 
P 
18-24  1.6  =    =  = 2.3 =    =  = 
25-44  2.6  1.7  0.2 to 13.6  0.3  NS  4.2  1.9  0.9 to 3.8  1.2  NS 
45-64  2.6  1.7  0.2 to 13.6  0.3  NS  8.2  3.8  1.5 to 9.3  8.4  P=0.004 
>64  4.9  3.2  0.8 to 12.9  2.8  NS  7.4  4.8  2.0 to 11.4  10.8  P<0.001 100    Clinical Practice & Epidemiology in Mental Health, 2010, Volume 6  Carta et al. 
A number of population surveys have shown that the AD 
usage increase is associated with a better response to the 
needs of patients with a diagnosis of depression [3]. How-
ever, the appropriateness of AD prescription is still open to 
debate. 
An Italian survey [5] found that only about 21% of those 
who may benefit from an AD, actually receive such drugs. 
This value was even lower than that (39%) found by Bellan-
tuono et al. [14] in another Italian investigation. Taken to-
gether, the low proportion of coverage in both studies 
strongly indicates that in Italy most patients affected by a 
clinically relevant depressive state do not receive antidepres-
sant drugs. For over a decade (1991 to 2002), in the Italian 
region Sardinia, the number of individuals with a defined 
diagnosis of depression, who were taking AD, increased 
from 8% to 40%. 
In this study, 38% of males and 57% of females had a 
lifetime diagnosis of MDD and were taking antidepressant 
drugs. Cross comparison of the present data with findings of 
other national and international studies is of particular inter-
est, although the results of this comparison should be consid-
ered with caution in view of the different sampling tech-
niques applied and type of instruments used. 
If the field is restricted to recent studies performed using 
tools based on the CIDI interview [15], an important finding 
which emerges is that the proportion of subjects with a diag-
nosis of depressive episode who were on antidepressants is 
markedly higher than the proportion reported in similar stud-
ies from Italy and North America; in fact a Canadian study 
reported that 14.9% of depressed subjects "in the commu-
nity" were treated with antidepressants whilst the renowned 
USA National Comorbidity Survey reported a figure of only 
7.3% [16]. In part, this positive result may be likely deter-
mined by the possibility of free access health services oper-
ated by the National Health System in Italy. Even with this 
said, the Esemed study in Italy indicates that only 10% of 
people with diagnosed MDD in the last 12 months have been 
taking antidepressant drugs (http://www.iss.it/pres/prim/ 
cont.php?id=854&tipo=6&lang=1). Thus it is correct to af-
firm that the correspondence between lifetime MDD diagno-
sis and use of antidepressant drugs in the present study was 
closer than reported by the literature that used non clinical 
interviewers. 
A source of difference may be the different measure of 
MDD frequencies used in the studies for assessing the asso-
ciation between antidepressant and MDD diagnosis. Our 
survey used lifetime prevalence due to the fact that several 
evidences show the efficacy in the long term treatment (three 
or more years) of antidepressants for MDD [17], thus a long 
term assumption may be evidence based. 
In every way, also in the light of a probably better condi-
tion than other settings, it is worth noting that more than 
50% of people are assuming antidepressant drugs without a 
lifetime diagnosis of MDD. This confirms the broad use of 
AD for indications other than depressive disorders. 
This study was supported by a grant of AIFA (Agenzia 
Italiana del Farmaco) Number FARM54S73S, approved in 
2005. 
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